KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Treasury Shares (2016 - 2025)

Boston Scientific's Treasury Shares history spans 15 years, with the latest figure at $2.3 billion for Q4 2025.

  • For Q4 2025, Treasury Shares changed 0.0% year-over-year to $2.3 billion; the TTM value through Dec 2025 reached $2.3 billion, changed 0.0%, while the annual FY2025 figure was $2.3 billion, 0.0% changed from the prior year.
  • Treasury Shares for Q4 2025 was $263.0 million at Boston Scientific, roughly flat from $263.3 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $263.3 million in Q1 2021 and bottomed at $9.3 million in Q4 2023.
  • The 5-year median for Treasury Shares is $263.3 million (2021), against an average of $208.9 million.
  • The largest YoY upside for Treasury Shares was 31.1% in 2021 against a maximum downside of 0.0% in 2021.
  • A 5-year view of Treasury Shares shows it stood at $2.3 billion in 2021, then changed by 0.0% to $2.3 billion in 2022, then changed by 0.0% to $2.3 billion in 2023, then changed by 0.0% to $2.3 billion in 2024, then changed by 0.0% to $2.3 billion in 2025.
  • Per Business Quant, the three most recent readings for BSX's Treasury Shares are $2.3 billion (Q4 2025), $2.3 billion (Q4 2024), and $2.3 billion (Q2 2024).